Glutamatergic transmission in schizophrenia

Kantrowitz, 2010, N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia Brain Res, Bull, 83, 108

Kantrowitz, 2010, Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models., Clin Schizophr Relat Psychoses, 4, 189, 10.3371/CSRP.4.3.6

Nicoletti, 2011, Metabotropic glutamate receptors: from the workbench to the bedside., Neuropharmacology, 60, 1017, 10.1016/j.neuropharm.2010.10.022

Krystal, 2011, Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists., CNS Drugs, 24, 669, 10.2165/11533230-000000000-00000

Moghaddam, 2012, From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment., Neuropsychopharmacology, 37, 4, 10.1038/npp.2011.181

Ohnuma, 2011, Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry, 35, 29, 10.1016/j.pnpbp.2010.08.027

Hons, 2010, Glycine serum level in schizophrenia: relation to negative symptoms., Psychiatry Res, 176, 103, 10.1016/j.psychres.2009.11.008

Hanzawa, 2011, No association between glutathione-synthesis-related genes and Japanese schizophrenia., Psychiatry Clin Neurosci, 65, 39, 10.1111/j.1440-1819.2010.02157.x

Ohnuma, 2010, No association between DAO and schizophrenia in a Japanese patient population: a multicenter replication study., Schizophr Res, 118, 300, 10.1016/j.schres.2010.01.028

Leung, 2010, Acute dopamine andor serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants., Psychopharmacology (Berl), 208, 233, 10.1007/s00213-009-1723-0

Stone, 2011, Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation., Pharmacopsychiatry, 44, 33

Leitman, 2010, Sensory deficits and distributed hierarchical dysfunction in schizophrenia., Am J Psychiatry, 167, 818, 10.1176/appi.ajp.2010.09030338

Musso, 2011, Ketamine effects on brain function: simultaneous fMRIEEG during a visual oddball task., Neuroimage, 58, 508, 10.1016/j.neuroimage.2011.06.045

Broberg, 2010, Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia: gating of auditory-evoked potentials and prepulse inhibition., Behav Brain Res, 213, 142, 10.1016/j.bbr.2010.04.026

Karlsgodt, 2011, Reduced dysbindin expression mediates N-methyl-D-aspartate receptor hypofunction and impaired working memory performance., Biol Psychiatry, 69, 28, 10.1016/j.biopsych.2010.09.012

Kunii, 2011, Altered DARPP-32 expression in the superior temporal gyrus in schizophrenia., Prog Neuropsychopharmacol Biol Psychiatry, 35, 1139, 10.1016/j.pnpbp.2011.03.016

Nishiura, 2011, Profiles of DARPP-32 in the insular cortex with schizophrenia: a postmortem brain study., Prog Neuropsychopharmacol Biol Psychiatry, 35, 1901, 10.1016/j.pnpbp.2011.07.010

Hokyo, 2010, Habituation in prepulse inhibition is affected by a polymorphism on the NMDA receptor 2B subunit gene (GRIN2B)., Psychiatr Genet, 20, 191, 10.1097/YPG.0b013e32833a201d

Namba, 2011, NMDA receptor regulates migration of newly generated neurons in the adult hippocampus via disrupted-in-schizophrenia 1 (DISC1)., J Neurochem, 118, 34, 10.1111/j.1471-4159.2011.07282.x

Feng, 2010, Expressions of neuregulin 1beta and ErbB4 in prefrontal cortex and hippocampus of a rat schizophrenia model induced by chronic MK-801 administration., J Biomed Biotechnol, 2010, 859516, 10.1155/2010/859516

Kristiansen, 2010, Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia., Schizophr Res, 119, 198, 10.1016/j.schres.2010.02.1069

Tsai, 2010, Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis., Curr Pharm Des, 16, 522, 10.2174/138161210790361452

Singh, 2011, Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia., CNS Drugs, 25, 859, 10.2165/11586650-000000000-00000

Lane, 2010, A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia., Int J Neuropsychopharmacol, 13, 451, 10.1017/S1461145709990939

Sreekumar, 2009, Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression., Nature, 457, 910, 10.1038/nature07762

Umbricht, 2010, Glycine transporter type 1 (GLYT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia., Neuropharmacology, 35, S320

Pinard, 2010, Selective GlyT1 inhibitors: discovery of 4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenylmethanone (RG1678), a promising novel medicine to treat schizophrenia., J Med Chem, 53, 4603, 10.1021/jm100210p

Kantrowitz, 2010, High dose D-serine in the treatment of schizophrenia., Schizophr Res, 121, 125, 10.1016/j.schres.2010.05.012

Norberg, 2008, A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy., Biol Psychiatry, 63, 1118, 10.1016/j.biopsych.2008.01.012

Fisher, 2009, Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia., Am J Psychiatry, 166, 805, 10.1176/appi.ajp.2009.08050757

Gottlieb, 2011, D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia., Schizophr Res, 35, 1901

Kinon, 2011, A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia., J Clin Psychopharmacol, 31, 349, 10.1097/JCP.0b013e318218dcd5

Stefani, 2010, Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade., Eur J Pharmacol, 639, 26, 10.1016/j.ejphar.2010.01.028

Miyake, 2011, Imaging changes in glutamate transmission in vivo with the metabotropic glutamate receptor 5 tracer 11C ABP688 and N-acetylcysteine challenge., Biol Psychiatry, 69, 822, 10.1016/j.biopsych.2010.12.023

Hackler, 2010, Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation., Neuroscience, 168, 209, 10.1016/j.neuroscience.2010.02.057

Chiusaroli, 2010, Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat., Pharmacol Res, 61, 430, 10.1016/j.phrs.2009.12.010

Smith, 2010, The therapeutic potential of D-amino acid oxidase (DAAO) inhibitors., Open Med Chem J, 4, 3, 10.2174/1874104501004020003

Ferraris, 2011, Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia., Curr Pharm Des, 17, 103, 10.2174/138161211795049633

Strick, 2011, Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain., Neuropharmacology, 61, 1001, 10.1016/j.neuropharm.2011.06.029

DeVito, 2011, Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology., Genes Brain Behav, 10, 210, 10.1111/j.1601-183X.2010.00656.x

Bado, 2011, Effects of low-dose D-serine on recognition and working memory in mice., Psychopharmacology (Berl), 218, 461, 10.1007/s00213-011-2330-4

Shimazaki, 2010, D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats., Psychopharmacology (Berl), 209, 263, 10.1007/s00213-010-1794-y